Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Merck
Mallinckrodt
AstraZeneca
Moodys

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

ULTIVA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Ultiva, and what generic alternatives are available?

Ultiva is a drug marketed by Mylan Institutional and is included in one NDA.

The generic ingredient in ULTIVA is remifentanil hydrochloride. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the remifentanil hydrochloride profile page.

Drug patent expirations by year for ULTIVA
Drug Prices for ULTIVA

See drug prices for ULTIVA

Recent Clinical Trials for ULTIVA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Helse FonnaPhase 4
University Hospital, AkershusPhase 4
Saint-Pierre University HospitalN/A

See all ULTIVA clinical trials

Recent Litigation for ULTIVA

Identify potential future generic entrants

District Court Litigation
Case NameDate
Mylan Pharma Acquisition Ltd. v. Fresenius Kabi USA, LLC2015-07-30

See all ULTIVA litigation

Pharmacology for ULTIVA
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Synonyms for ULTIVA
1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester
1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester, monohydrochloride
1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-, methyl ester
132539-07-2
132539-07-2 (mono-hydrochloride)
132875-61-7
132875-61-7 (Parent)
3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
3-[methoxycarbonyl-4-[(1-oxopropyl)phenylamino]1-piperidine]propanoic acid methyl ester hydrochloride
4-(methoxycarbonyl)-1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidinium chloride
4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-1-piperidinepropanoic acid methyl ester
4-(Methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic Acid Methyl Ester Hydrochloride
4-Carboxy-4-(N-phenylpropionamido)-1-piperidine propionic acid, dimethyl ester, monohydrochloride
4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
5V444H5WIC
AC1L1TZ5
AC1L1TZ8
AC1Q3E9W
AC1Q5ZGR
API0004789
BIDD:GT0029
C-21265
C08021
C20H28N2O5.HCl
CC-34231
CHEBI:32091
CHEBI:8802
CHEMBL1005
CHEMBL1201120
D01177
D08473
DB00899
DEA No. 9739
DTXSID00157826
DTXSID50157614
FT-0631145
FT-0674340
GI 87084B
GI 87084X
GI-87084B
GI87084B
GTPL7292
HSDB 8377
L001266
LS-115982
LS-172838
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-phenylpropanamido)piperidine-4-carboxylate
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate hydrochloride
methyl 1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate
methyl 1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate hydrochloride
methyl-1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidin-4-carboxylathydrochlorid
P10582JYYK
REMIFENTANIL
Remifentanil (INN)
Remifentanil [INN:BAN]
Remifentanil HCl
REMIFENTANIL HYDROCHLORIDE
Remifentanil hydrochloride (JAN/USAN)
Remifentanil hydrochloride [USAN]
Remifentanil hydrochloride solution, 100 mug/mL in methanol (as free base), certified reference material
Remifentanil hydrochloride, >=97% (HPLC), powder
Remifentanil hydrochloride, European Pharmacopoeia (EP) Reference Standard
remifentanil monohydrochloride
Remifentanyl
Remifentanyl Hydrochloride
SB17331
SB17332
SCHEMBL36652
SCHEMBL41242
Ultiva (TN)
UNII-5V444H5WIC
UNII-P10582JYYK
ZINC538283
ZTVQQQVZCWLTDF-UHFFFAOYSA-N
Paragraph IV (Patent) Challenges for ULTIVA
Tradename Dosage Ingredient NDA Submissiondate
ULTIVA INJECTABLE;INJECTION remifentanil hydrochloride 020630 2013-12-27

US Patents and Regulatory Information for ULTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 AP RX Yes No   Start Trial   Start Trial   Start Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 AP RX Yes No   Start Trial   Start Trial   Start Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ULTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996   Start Trial   Start Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996   Start Trial   Start Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996   Start Trial   Start Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Medtronic
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.